Matthew D. Galsky, MD, on Key Takeaways from ASCO 2021 Bladder Cancer Annual Meeting

At the 2021 American Society of Clinical Oncology (ASCO) annual meeting, CancerNetwork® spoke with Matthew D. Galsky, MD, of Mount Sinai Hospital in New York, about approaches to protect the bladder from bladder cancer and how the new data may motivate more clinicians to use these treatment strategies. Galsky and colleagues presented the results of a study combining bladder preservation surgery and systemic neoadjuvant therapy with nivolumab and chemotherapy.


I think the biggest impact of studies conducted at ASCO this year in the area of ​​bladder cancer probably has to do with bladder preservation approaches. They really mark a new dawn in bladder cancer bladder-saving approaches in terms of integrating immune checkpoint blockage with radiation, or even without radiation in terms of bladder-saving testing. This is an approach that, of course, has been used for decades. This is the standard of care. There is level one evidence for the approach, although it is not practiced as frequently in some parts of the world as others. It may be that the integration of a new treatment modality in the field of bladder preservation is a necessary tipping point to truly [motivate] the community to adopt this as a reasonable option for bladder cancer patients.


Galsky MD, Daneshmand S, Chan KG, et al. Phase 2 trial of gemcitabine, cisplatin and nivolumab with selective bladder sparing in patients with muscle invasive bladder cancer (MIC): HCRN GU 16-257. J Clin Oncol. 2021; 39 (suppl 15): 4503. doi: 10.1200 / JCO.2021.39.15_suppl.4503

About Hector Hedgepeth

Check Also

Putting a new spin on football’s spiral — ScienceDaily

Only a handful of researchers have studied why an American football flies in such a …

Leave a Reply

Your email address will not be published.